🧾 What This Document Is 📰

This document is a summary of a Current Report (Form 8-K) filed by Perspective Therapeutics, Inc. It was triggered by the company presenting updated interim data on one of its core drugs at the American Association for Cancer Research (AACR) Annual Meeting in April 2026.

In simple terms, this is a scientific progress report. It details the safety and efficacy results of a clinical trial for a new type of radioactive cancer therapy. These updates are crucial because they show whether the drug is working and if it is safe for more patients to use.

👉 The main headline finding is that the company's therapy, [²¹²Pb]VMT-α-NET, remains well-tolerated, and the efficacy data continues to show promising anti-tumor activity across multiple cohorts.

🧬 What Perspective Therapeutics Does 🎗️

Perspective Therapeutics, Inc. is a specialized radiopharmaceutical development company. This means they focus on creating drugs that use radioactive isotopes (like Lead-212, or [²¹²Pb]) to deliver radiation directly to cancer cells.

The company's approach is called "theranostics." This is a clever combination of technology that allows them to first see the specific tumor using an imaging agent, and then treat it with a therapeutic agent that uses the same targeting mechanism.

👉 The company has developed proprietary technology that utilizes the alpha-emitting isotope [²¹²Pb], which is highly effective at delivering radiation specifically to cancer sites, potentially improving treatment efficiency while minimizing damage to healthy tissue.

🧪 [²¹²Pb]VMT-α-NET: The Core Therapy 🚀

The primary focus of the update is the drug [²¹²Pb]VMT-α-NET. This therapy is specifically designed to target Somatostatin Receptor Subtype 2 (SSTR2), which is a receptor often found on the surface of Neuroendocrine Tumors (NETs).

This drug is potentially the first-in-class radiopharmaceutical therapy targeting SSTR2. The company is running a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) to test its safety and effectiveness in patients with unresectable or metastatic SSTR2-positive NETs.

👉 [²¹²Pb]VMT-α-NET is a powerful, targeted treatment that makes sense because it locks onto specific receptors (SSTR2) on the tumor, maximizing the dose right where it's needed.

🛡️ Safety Data and Tolerability 🩺

The clinical update featured data from 64 patients across three different dose cohorts (2.5 mCi, 5.0 mCi, and 6.0 mCi). Overall, the therapy has shown a compelling safety profile.

The results are very positive:

• There were no reports of dose limiting toxicities (DLTs), serious renal complications, dysphagia, or clinically significant treatment-related myelosuppression.
• The most common Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 23 patients (36%).
• The only serious adverse events (SAEs) reported—such as pyrexia/vomiting or foot fracture—were noted in five patients, but none were deemed related to the study medication.

👉 Overall, the drug remains well-tolerated, suggesting that the therapeutic benefits may outweigh the manageable side effects, which is a major positive for drug development.

📈 Anti-Tumor Activity and Efficacy 🔬

The efficacy data tracks the drug's ability to shrink or eliminate tumors. The updates included analysis from Cohort 2 (23 patients in the 5.0 mCi group), which showed encouraging anti-tumor activity.

Key findings related to tumor response include:

• Objective Response Rate: In Cohort 2, ten out of 23 patients (43%) were observed to have an objective response according to the RECIST v1.1 criteria.
• Deepening Response: Nine patients were observed to have a deepening of their best response since the previous presentation at ESMO in October 2025, indicating sustained and improving treatment effectiveness.
• Disease Control: Of the 25 patients in Cohort 1 and Cohort 2, 18 patients (72%) remained without progression and were still alive, suggesting durable disease control.

👉 The increasing and deepening objective responses suggest that the drug's effectiveness might continue to grow, rather than plateauing after initial treatment cycles.

🧪 The Full Oncology Portfolio 🧬

While [²¹²Pb]VMT-α-NET is the focus, Perspective is building a broader oncology platform. The company is advancing two other proprietary lead-212 programs in Phase 1/2a trials:

• VMT01 (Melanoma): This program targets MC1R and is being tested in an open-label trial for Melanoma. Preliminary anti-tumor activity has been observed, and the drug is also noted as being well-tolerated.
• PSV359 (Solid Tumors): This program targets FAP-ɑ and is being tested in an open-label Phase 1/2a trial for advanced solid tumors. The company notes that PSV359 has shown improved tumor retention, which is a promising trait for a therapeutic agent.

👉 Having multiple, distinct programs (NETs, Melanoma, Solid Tumors) all built on the same proprietary lead-212 platform significantly de-risks the company and expands its market potential.

🧭 Future Strategy and Optionality 🗺️

Management provided strong commentary regarding the future direction of the drug and the company. Markus Puhlmann, Chief Medical Officer, stated that "Updated analyses continue to support the compelling overall clinical profile of [²¹²Pb]VMT-α-NET as a treatment for GEP-NETs at the Cohort 2 dose level of 5 mCi per dose or up to 20 mCi cumulatively."

He further emphasized the strategic path forward:

• Optimization: They are continually enhancing their robust clinical package by adding optionality with additional dose cohorts and looking beyond the current target of Gastrointestinal NETs (GEP-NETs).
• Goal: The company is working to establish a broad therapeutic window for GEP-NETs to support a potential registration study.
• Timing: They expect to receive initial efficacy data from an additional 23 patients in Cohort 2 and eight patients in Cohort 3 later this year.

👉 This planned expansion into multiple dose cohorts and different tumor types signals a strategy of maximizing the drug's utility and building a comprehensive, marketable treatment option.

📞 Investor Relations and Next Steps 📬

If you wish to follow up on this data or learn more about the company, they provided clear contact information and highlighted future opportunities.

• Investor Relations Contact: Annie J. Cheng, CFA
• Email: [email protected]
• Website: www.perspectivetherapeutics.com

The company also outlined a clear path for future development, stating that Phase 1/2 data is expected across all three clinical programs (VMT-α-NET, VMT01, PSV359) in 2026.

🧠 The Analogy

Think of Perspective Therapeutics like a high-precision artillery unit. Instead of using a general blast (like traditional chemotherapy) that hits both the bad guys (cancer) and the good guys (healthy cells), they are developing specialized "smart bombs." These smart bombs (the radiosignaling drugs) are engineered to attach to a specific chemical signature found only on the enemy's tank (the SSTR2 receptor on the tumor). They deliver the payload (the radioactive lead-212) right to the target, maximizing damage to the cancer while keeping the collateral damage low.

🧩 Final Takeaway

Perspective Therapeutics has presented strong, reinforcing data for [²¹²Pb]VMT-α-NET, showing continuous improvement in tumor response (43% objective response) and maintaining a positive safety profile. The combination of positive clinical results, a deep understanding of the target (SSTR2), and a diverse pipeline (Melanoma, Solid Tumors) positions the company to advance toward full drug registration.